Biohaven Pharmaceutical Holding Company Ltd. Common Shares (BHVN): Price and Financial Metrics


Biohaven Pharmaceutical Holding Company Ltd. Common Shares (BHVN): $19.34

0.52 (+2.76%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BHVN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BHVN Stock Price Chart Interactive Chart >

Price chart for BHVN

BHVN Price/Volume Stats

Current price $19.34 52-week high $20.07
Prev. close $18.82 52-week low $5.54
Day low $19.01 Volume 42,130
Day high $19.84 Avg. volume 996,052
50-day MA $15.99 Dividend yield N/A
200-day MA $0.00 Market Cap 1.32B

Biohaven Pharmaceutical Holding Company Ltd. Common Shares (BHVN) Company Bio


Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. The company was founded in 2013 and is based in New Haven, Connecticut.


BHVN Latest News Stream


Event/Time News Detail
Loading, please wait...

BHVN Latest Social Stream


Loading social stream, please wait...

View Full BHVN Social Stream

Latest BHVN News From Around the Web

Below are the latest news stories about BIOHAVEN LTD that investors may wish to consider to help them evaluate BHVN as an investment opportunity.

Do investors need to be concerned about Biohaven Ltd. (BHVN)?

The share price of Biohaven Ltd. (NYSE:BHVN) rose to $19.20 per share on Monday from $18.44. While Biohaven Ltd. has overperformed by 4.12%, investors are advised to look at stock chart patterns for technical insight. On January 04, 2023, JP Morgan started tracking Biohaven Ltd. (NYSE: BHVN) recommending Overweight. A report published by BTIG Research […]

US Post News | January 24, 2023

Jim Cramer Says This Stock Up 23% In A Month Is ''A Great Speculative Buy''

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Biohaven Ltd (NYSE: BHVN ) is a "great speculative buy." Analysts agree, Benzinga data shows a consensus Overweight rating on BHVN. When asked about Boston Properties Inc (NYSE: … Full story available on Benzinga.com

Benzinga | January 18, 2023

Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference

NEW HAVEN, Conn., Jan. 6, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California, on…

PR Newswire | January 6, 2023

J.P. Morgan Says These 2 Stocks Are Ready to Rip Higher — This Is What Makes Them Attractive Buys

Wrapping up the first trading week of the New Year, it’s clear that last year’s headwinds haven’t left us. Inflation remains high, the Fed has signaled that it will keep interest rates higher, longer, in response, and negative economic indicators keep piling up, pointing toward an increased likelihood of recession. The challenge for investors hasn’t really changed: to build a portfolio that will pay, even in this difficult market environment. Times like this call for a guiding hand, perhaps some

Yahoo | January 6, 2023

Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?

Here is how Biohaven Ltd. (BHVN) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Yahoo | January 5, 2023

Read More 'BHVN' Stories Here

BHVN Price Returns

1-mo 43.26%
3-mo 25.02%
6-mo N/A
1-year N/A
3-year -60.70%
5-year -39.68%
YTD 39.34%
2022 -89.93%
2021 60.79%
2020 57.44%
2019 47.21%
2018 37.06%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6959 seconds.